Glanzmann's thrombasthenia (GT) is an autosomal recessive disorder of platelet function. Conventional management is by platelet transfusion, given before invasive interventions. Alloimmunization resulting in platelet refractoriness and an unpredictable response to platelet infusion have provided particular management difficulties in the past. More recently recombinant (r)VIIa (Novoseven) has a valuable role in the treatment of platelet function disorders. Treatment of a patient with GT during two pregnancies and spinal surgery is reported. An algorithm is presented to provide a structured and consistent approach to treatment.
1. O'Toole TE, Loftus JC, Plow EF, et al. Efficient surface expression of platelet GPIIb-IIIa requires both subunits. Blood1989;74(1):14-14.
2.
2. George JN, Caen JP, Nurden AT.Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood1990;75(7):1383-1383.
3.
3. Favaloro EJ.Clinical application of the PFA-100. Curr Opin Hematol2002;9:407-407.
4.
4. Walters JP, Hall J, St E.Glanzmann's thrombasthenia and pregnancy. WI Med J1990;39(4):256-256.
5.
5. Ito K, Yoshida H, Hatoyama H, et al. Antibody removal therapy used sucessfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple antiplatelet antibodies. Vox Sang1991;61:40-40.
6.
6. Jallu V, Pico M, Chevaleyre J, et al. Characterization of an antibody to the integrin 03 subunit (GP IIIa) from a patient with neonatal thrombocytopenia and an inherited deficiency of GP IIb-IIIa complexes in platelets (Glanzmann's thrombasthenia). Hum Antibod Hybridomas1992;3:93-93.
7.
7. BCSH. Guidelines for platelet transfusions. Trans Med1992;2:311-311.
9. TRAP. Leucocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med1997;337:1861-1861.
10.
10. Novotny VMJ, Huizinga TWJ, van Doorn R, et al. HLA class 1-eluted platelets as an alternative to HLA-matched platelets. Transfusion1996;36:438-438.
11.
11. Conte R, Cirillo D, Ricci F, et al. Platelet transfusion in a patient affected by Glanzmann's thrombasthenia with antibodies against GPIIb-IIIa. Haematologica1997;82:73-73.
12.
12. Friedberg RC, Donnelly SF, Boyd JC, et al. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood1993;81:3428-3428.
13.
13. Hedner U.Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol2001;38(suppl 12):43-43.
14.
14. Poon M, Demers C, Jobin F, et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood1999;94:3951-3951.
15.
15. Poon M-C, d'Oiron R, Hann I, et al. Use of recombinant factor VIIa (Novoseven) in patients with Glanzmann thrombasthenia. Semin Haematol2001;38(suppl 12):21-21.
16.
16. Roberts HR.Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol2001;38(suppl 12):48-48.
